Recombinant Human CLEC-2/CLEC1B Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CLEC-2/CLEC1B Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human Podoplanin Fc Chimera (Catalog # 3670-PL) can bind Recombinant Human CLEC-2/CLEC1B with an estimated K_d <4 nM.
• Source: Mouse myeloma cell line, NS0-derived human CLEC-2/CLEC1B protein
  Gln58-Pro229, with an N-terminal 10-His tag
• Accession #: AAF36777
• N-terminal Sequence: His
• Protein/Peptide Type: Recombinant Proteins
• Gene: CLEC1B
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 21.8 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 29-36 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CLEC-2/CLEC1B Protein, CF

• 1810061I13Rik
• CLEC1B
• CLEC2
• CLEC-2
• CLEC2B
• CLEC2PRO1384
• C-type lectin domain family 1 member B
• C-type lectin domain family 1, member B
• C-type lectin-like receptor 2
• C-type lectin-like receptor-2
• QDED721

Background

C-type lectin-like receptor 2 (CLEC-2) is a 32 kDa, type II transmembrane glycoprotein and member of the C-type lectin-like family of receptors (1-4). CLEC-2 consists of a 33 amino acid (aa) cytoplasmic domain, a 21 aa transmembrane region, and a 175 aa extracellular domain (SwissProt # Q9P126). The cytoplasmic domain contains multiple threonine and serine residues which are sites of potential phosphorylation, and a YXXL (Tyr-Xaa-Xaa-Leu) motif through which CLEC-2 does its signaling (2, 4-5). Ligand binding and cross-linking of CLEC-2 induces Src kinase-dependent tyrosine phosphorylation of the YXXL sequence, inducing activation of the tyrosine kinase Syk and initiation of a signaling pathway that culminates in activation of phospholipase C gamma 2 (2, 5). The extracellular domain contains three potential sites of N-linked glycosylation, and a single carbohydrate recognition domain (CRD) which shows conservation of six cysteine residues (1, 6). Unlike most other members of the C-type lectin-like family of receptors, CLEC-2's CRD lacks the amino acid residues that are crucial for Ca2⁺-dependent carbohydrate binding, making it a non-classical C-type lectin receptor (1, 6). A splicing variant at aa 22-55 produces two isoforms for CLEC-2. Isoform 1 is the longer protein, and in isoform 2, an alanine residue is substituted for aa 22-55. Human CLEC-2 shares 63% aa sequence identity with mouse CLEC-2. CLEC-2 is expressed preferentially in liver, and is also detected in myeloid cells (monocytes, dendritic cells, and granulocytes) (1), platelets, and megakaryocytes (4). CLEC-2 is the receptor for the platelet-aggregating snake venom protein rhodocytin (3 - 4) and the molecule podoplanin, a transmembrane sialoglycoprotein that, when bound to CLEC-2, is involved in platelet aggregation, tumor metastasis, and lymphatic vessel formation (2, 7). CLEC-2 has also been shown to enhance infectivity of HIV-1 by mediating HIV-1 attachment and transfer by CLEC-2 transfected cells and platelets (8).

1. Colonna, M. et al. (2000) Eur. J. Immunol. 30:697.
2. Christou, C.M. et al. (2008) Biochem. J. 411:133.
3. Watson, A.A. et al. (2007) J. Biol. Chem. 282:3165.
4. Suzuki-Inoue, K. et al. (2006) Blood 107:542.
5. Fuller, G.L. et al. (2007) J. Biol. Chem. 282:12397.
6. Weis, W.I. et al. (1998) Immunol. Rev. 163:19.
7. Suzuki-Inoue, K. et al. (2007) J. Biol. Chem. 282:25993.
8. Chaipan, C. et al. (2006) J. Virol. 80:8951.

Publications for CLEC-2/CLEC-1B (1718-CL)(4)

Publications using 1718-CL

• Lien, TS;Sun, DS;Chang, HH; Targeted Delivery to Dying Cells Through P-Selectin-PSGL-1 Axis: A Promising Strategy for Enhanced Drug Efficacy in Liver Injury Models Cells 2024-10-27 [PMID: 39513885] (Bioassay, N/A)
• LSC Ward, L Sheriff, JL Marshall, JE Manning, A Brill, GB Nash, HM McGettrick Podoplanin regulates the migration of mesenchymal stromal cells and their interaction with platelets J. Cell. Sci., 2019-02-25;0(0):. 2019-02-25 [PMID: 30745334] (Bioassay, Human)
• L Sheriff, A Alanazi, LSC Ward, C Ward, H Munir, J Rayes, M Alassiri, SP Watson, PN Newsome, GE Rainger, N Kalia, J Frampton, HM McGettrick, GB Nash Origin-Specific Adhesive Interactions of Mesenchymal Stem Cells with Platelets Influence Their Behavior After Infusion Stem Cells, 2018-03-23;0(0):. 2018-03-23 [PMID: 29488279] (Bioassay, Human)
• Chang C, Chung C, Hsu C, Peng H, Huang T Inhibitory effects of polypeptides derived from a snake venom C-type lectin, aggretin, on tumor cell-induced platelet aggregation. J Thromb Haemost, 2014-04-01;12(4):540-9. 2014-04-01 [PMID: 24479713] (Bioassay)

Bioinformatics

• Gene Symbol: CLEC1B
• Uniprot:
  • AAF36777()